What is it about?

The paper focuses on a clinical trial that meticulously compares the safety and effectiveness of Unani formulations and PUVAsol in addressing non-segmental vitiligo, a long-lasting autoimmune pigmentary disorder distinguished by patches and macules of reduced pigmentation. The trial involved 82 participants aged between 18 and 40 years, with the primary assessment based on the variation in vitiligo area scoring index (VASI) observed at weeks 4, 8, 12, and 16. The study ultimately deduced that both treatments exhibited comparable efficacy and were well-tolerated among patients with non-segmental vitiligo.

Featured Image

Why is it important?

This paper holds significant importance as it presents compelling scientific evidence regarding the safety and effectiveness of Unani formulations as compared to PUVAsol in the treatment of non-segmental vitiligo, a widespread and emotionally distressing condition. The study's discoveries have the potential to empower physicians and patients with valuable information when considering treatment options for vitiligo.


I am hopeful that this research will bring significant benefits to the scientific community, particularly in the field of Unani medicine. The Unani system possesses a wealth of therapeutic knowledge encapsulated in classical books, pharmacopoeias, and formularies. However, there is a dearth of scientific validation for these resources. By addressing this gap, this research has the potential to unlock the true potential of Unani medicine and establish its credibility through scientific evidence.

Dr. Nazim Husain
Luqman Unani Medical College Hospital and Research Center, Bijapur, Karnataka, India

Read the Original

This page is a summary of: A non-inferiority randomized controlled clinical trial comparing Unani formulations & PUVAsol in non-segmental vitiligo, Journal of Complementary and Integrative Medicine, June 2021, De Gruyter, DOI: 10.1515/jcim-2021-0057.
You can read the full text:



The following have contributed to this page